Clinical Trials on Small Cell Prostate Cancer in Japan

Total 531 results

Pfizer

Active, not recruiting

Sasanlimab (PF-06801591, PD-1 Inhibitor) in Participants With Advanced Malignancies

Non-small-cell Lung Cancer | Advanced Malignancies

China, Korea, Republic of, Taiwan, Japan, Russian Federation, Ukraine
Eli Lilly and Company

Completed

A Study of LY3295668 Erbumine in Participants With Extensive-stage Small-Cell Lung Cancer

Small Cell Lung Cancer

France, Belgium, Spain, United States, Korea, Republic of, Japan, United Kingdom, Turkey
Daiichi Sankyo
Merck Sharp & Dohme LLC; AstraZeneca

Active, not recruiting

Datopotamab Deruxtecan (Dato-DXd) in Combination With Pembrolizumab With or Without Platinum Chemotherapy in Subjects With Advanced or Metastatic Non-Small Cell Lung Cancer (TROPION-Lung02)

Advanced or Metastatic NSCLC

United States, Spain, Taiwan, Japan, Italy
Sanofi

Completed

Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer (FIRSTANA)

Prostate Cancer

Australia, Portugal, Spain, Peru, Sweden, Romania, Russian Federation, Belarus, Israel, France, Italy, Denmark, Turkey, Germany, United States, Brazil, Canada, China, Czechia, Finland, Japan, Mexico, Poland, Taiwan, Ukraine
Myovant Sciences GmbH

Completed

A Study to Evaluate the Safety and Efficacy of Relugolix in Men With Advanced Prostate Cancer (HERO)

Prostate Cancer

United States, Germany, Spain, New Zealand, Brazil, Belgium, Australia, Austria, Canada, China, Denmark, Finland, France, Italy, Japan, Korea, Republic of, Netherlands, Poland, Slovakia, Sweden, Taiwan, United Kingdom
Hoffmann-La Roche

Active, not recruiting

A Study of Neoadjuvant Atezolizumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Patients With Resectable Stage II, IIIA, or Select IIIB Non-Small Cell Lung Cancer (IMpower030)

Non-Small-Cell Lung

United States, Korea, Republic of, United Kingdom, Australia, France, Italy, Spain, Japan, Brazil, China, Germany, Poland, Thailand, Israel, Switzerland, Taiwan, Austria, Russian Federation, Ukraine, Hungary, Serbia, Slovenia, South... and more
AstraZeneca

Completed

A Study of IRESSA Treatment Beyond Progression in Addition to Chemotherapy Versus Chemotherapy Alone (IMPRESS)

Non-Small Cell Lung Cancer

Italy, Spain, France, Korea, Republic of, Hungary, Japan, China, Taiwan, Hong Kong, Germany, Russian Federation
Pfizer
Astellas Pharma Inc; Medivation LLC, a wholly owned subsidiary of Pfizer Inc.

Completed

A Safety and Efficacy Study of Oral MDV3100 in Chemotherapy-Naive Patients With Progressive Metastatic Prostate Cancer (PREVAIL)

Prostate Cancer

Canada, United States, Spain, Australia, Denmark, Korea, Republic of, Belgium, Singapore, Finland, Netherlands, France, Austria, Germany, Israel, United Kingdom, Italy, Japan, Lithuania, Poland, Russian Federation, Slovakia, Sweden
Astellas Pharma Global Development, Inc.
Medivation LLC, a wholly owned subsidiary of Pfizer Inc.

Active, not recruiting

A Study of Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus ADT in Patients With Metastatic Hormone Sensitive Prostate Cancer (mHSPC) (ARCHES)

Metastatic Hormone Sensitive Prostate Cancer

Korea, Republic of, Japan, United States, Argentina, Australia, Belgium, Canada, Chile, Denmark, Finland, France, Germany, Israel, Italy, Netherlands, New Zealand, Poland, Romania, Russian Federation, Slovakia, Spain, Sweden, Taiwan, United...
EMD Serono Research & Development Institute, Inc.
Merck KGaA, Darmstadt, Germany

Completed

Avelumab in First-line NSCLC (JAVELIN Lung 100)

First Line Non-Small Cell Lung Cancer

Spain, United States, Hungary, Israel, China, Korea, Republic of, Taiwan, Czechia, Russian Federation, Australia, Brazil, Lebanon, Serbia, Thailand, Canada, Slovakia, Ukraine, Bulgaria, Italy, Netherlands, New Zealand, Poland, Belgium, Turk... and more
AbbVie

Recruiting

Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer (NSCLC), Head and Neck Squamous Cell Carcinoma (HNSCC) and Other Solid Tumors, Receiving Intravenous (IV) Infusion of ABBV-514 Alone or in Combination With Budigalimab

Non-Small Cell Lung Cancer | Head and Neck Squamous Cell Carcinoma

United States, Japan, Israel, Korea, Republic of
Millennium Pharmaceuticals, Inc.

Completed

Study Comparing Orteronel Plus Prednisone in Participants With Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer

Prostate Cancer

United States, France, Ukraine, United Kingdom, Belgium, Germany, Taiwan, Spain, Belarus, Israel, Portugal, Bulgaria, Romania, South Africa, Japan, Switzerland, Canada, Australia, Netherlands, Greece, Chile, New Zealand, Peru, Singapore, Russian Federation and more
Bayer
Orion Corporation, Orion Pharma

Completed

Darolutamide in Addition to Standard Androgen Deprivation Therapy and Docetaxel in Metastatic Hormone-Sensitive Prostate Cancer (ARASENS)

Metastatic Hormone-sensitive Prostate Cancer

Belgium, France, Sweden, China, Canada, United States, Spain, Taiwan, Japan, Finland, Korea, Republic of, Australia, Brazil, Czechia, Israel, Italy, Netherlands, Russian Federation, Bulgaria, United Kingdom, Germany, Poland, Mexico
AstraZeneca

Active, not recruiting

Study of Durvalumab Given With Chemoradiation Therapy in Patients With Unresectable Non-small Cell Lung Cancer

Non-Small Cell Lung Cancer

Poland, India, Thailand, Vietnam, Turkey, Korea, Republic of, Brazil, Czechia, Hungary, Japan, Mexico, Peru, Philippines, Russian Federation
Bayer

Recruiting

A Study to Compare Darolutamide Given With Androgen Deprivation Therapy (ADT) With ADT in Men With Hormone Sensitive Prostate Cancer and Raise of Prostate Specific Antigen (PSA) Levels After Local Therapies (ARASTEP)

Biochemically Recurrent Prostate Cancer

Austria, Spain, France, United States, Australia, Brazil, Germany, Taiwan, Denmark, China, Netherlands, Japan, Canada, Finland, Italy, Hungary, Portugal, United Kingdom, Poland, Israel, New Zealand, Sweden, Belgium, Czechia
Eli Lilly and Company
Loxo Oncology, Inc.

Recruiting

A Study of LY4101174 in Participants With Recurrent, Advanced or Metastatic Solid Tumors

Cervical Cancer | Pancreatic Cancer | Esophageal Cancer | Ovarian Cancer | Prostate Cancer | Bladder Cancer | Triple Negative Breast Cancer | Advanced Solid Tumor | Metastatic Solid Tumor | Non-small Cell Lung Cancer | Head and Neck Squamous Cell Carcinoma | Renal Pelvis Cancer | Urinary Bladder Neoplasm | Recurrent...

United States, Japan, Australia
Novartis Pharmaceuticals

Completed

LDK378 in Adult Patients With ALK-activated NSCLC Previously Treated With Chemotherapy and Crizotinib

Non-Small Cell Lung Cancer

Canada, Italy, United Kingdom, Spain, Netherlands, Singapore, Germany, Hong Kong, Japan, France, Korea, Republic of, United States
Bristol-Myers Squibb
Ono Pharmaceutical Co. Ltd

Completed

An Open-Label, Randomized, Phase 3 Trial of Nivolumab Versus Investigator's Choice Chemotherapy as First-Line Therapy for Stage IV or Recurrent PD-L1+ Non-Small Cell Lung Cancer (CheckMate 026)

Stage IV or Recurrent Non-Small Cell Lung Cancer

United States, Finland, Argentina, France, Italy, Brazil, Greece, Japan, Mexico, Romania, Spain, Sweden, United Kingdom, Australia, Austria, Belgium, Canada, Czechia, Germany, Hungary, Korea, Republic of, Netherlands, Poland, Switzerland and more
Merck Sharp & Dohme LLC
Eisai Inc.

Active, not recruiting

Efficacy and Safety of Pembrolizumab (MK-3475) With Lenvatinib (E7080/MK-7902) vs. Docetaxel in Participants With Metastatic Non-Small Cell Lung Cancer (NSCLC) and Progressive Disease (PD) After Platinum Doublet Chemotherapy and Immunotherapy (MK-7902-008/E7080-G000-316/LEAP-008)

Metastatic Non-Small Cell Lung Cancer

Russian Federation, Australia, United States, Argentina, Canada, Colombia, France, Germany, Greece, Hungary, Israel, Italy, Japan, Korea, Republic of, Portugal, Puerto Rico, Spain, United Kingdom
Genentech, Inc.
Hoffmann-La Roche

Completed

A Study of Onartuzumab (MetMAb) in Combination With Tarceva (Erlotinib) in Participants With Met Diagnostic-Positive Non-Small Cell Lung Cancer Who Have Received Chemotherapy For Advanced or Metastatic Disease (MetLung)

Non-Squamous Non-Small Cell Lung Cancer

Poland, Belgium, Spain, United States, Canada, South Africa, Russian Federation, Hong Kong, Taiwan, Japan, France, United Kingdom, Australia, Germany, Hungary, Korea, Republic of, Netherlands, Croatia, Serbia, Israel, Ukraine, Peru, Brazi... and more
AstraZeneca

Terminated

A Phase III Trial of ZD4054 (Zibotentan) (Endothelin A Antagonist) in Non-metastatic Hormone Resistant Prostate Cancer (ENTHUSE M0)

Prostate Cancer

Sweden, United States, Brazil, Czech Republic, France, Italy, Peru, Russian Federation, Spain, Turkey, United Kingdom, Germany, China, Hungary, Latvia, Poland, Romania, Japan, Finland, Norway, Canada, South Africa, Argentina, Australia, Belgiu... and more
AstraZeneca

Recruiting

Saruparib (AZD5305) vs Placebo in Men With Metastatic Castration-Sensitive Prostate Cancer Receiving Physician's Choice New Hormonal Agents (EvoPAR-PR01)

Metastatic Castration-Sensitive Prostate Cancer

United States, Canada, Spain, United Kingdom, Italy, Australia, Korea, Republic of, Belgium, Germany, Japan, Peru, France, China, India, Taiwan, Thailand, Austria, Brazil, Turkey, Malaysia, Finland, Netherlands, Chile, Hungary, Poland, Sw...
Hoffmann-La Roche

Recruiting

A Study to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Anti-tumor Activity of RO7616789 in Advanced Small Cell Lung Cancer and Other Neuroendocrine Carcinomas

Small Cell Lung Cancer | Neuroendocrine Carcinoma

United States, Japan, Denmark, Spain, Poland
AstraZeneca

Terminated

Phase I/II Study of AZD2171 in Combination With Paclitaxel/Carboplatin in Japanese Non-Small Cell Lung Cancer Patients

Carcinoma, Non-Small-Cell Lung

Japan
AstraZeneca

Recruiting

Savolitinib Plus Osimertinib Versus Platinum-based Doublet Chemotherapy in Participants With Non-Small Cell Lung Cancer Who Have Progressed on Osimertinib Treatment (SAFFRON)

Carcinoma | Non-Small-Cell Lung

China, Israel, Spain, United States, Canada, Italy, Korea, Republic of, Belgium, Bulgaria, Vietnam, Japan, United Kingdom, Brazil, France, Philippines, Taiwan, Thailand, Germany, Poland, Austria, Greece, Turkey, Malaysia, Argentina, Hong... and more
Ono Pharmaceutical Co. Ltd
Bristol-Myers Squibb

Completed

Study of ONO-4538 in Non-Squamous Non-Small Cell Lung Cancer (TASUKI-52)

Non-Small Cell Lung Cancer

Japan, Korea, Republic of, Taiwan
Gustave Roussy, Cancer Campus, Grand Paris
European Organisation for Research and Treatment of Cancer - EORTC

Completed

Radiation Therapy in Patients With Limited-Stage Small Cell Lung Cancer in Complete Remission

Lung Cancer

Korea, Republic of, France, Switzerland, Greece, Spain, Israel, Portugal, United Kingdom, Belgium, Netherlands, United States, Italy, Germany, Serbia, Chile, Turkey, Japan, South Africa, Poland, Australia, Romania, Colombia, Macedonia... and more
Merck Sharp & Dohme LLC
Eisai Inc.

Completed

Efficacy and Safety Study of Pembrolizumab (MK-3475) With or Without Lenvatinib (MK-7902/E7080) in Adults With Programmed Cell Death-Ligand 1 (PD-L1)-Positive Treatment-naïve Nonsmall Cell Lung Cancer (NSCLC) (MK-7902-007/E7080-G000-314/LEAP-007)

Non-small Cell Lung Cancer

China, Israel, United States, Australia, Canada, Colombia, Estonia, France, Hungary, Italy, Japan, Korea, Republic of, Malaysia, Mexico, Poland, Russian Federation, Taiwan, Turkey, Ukraine
AstraZeneca

Completed

Survey on the Treatment Reality of Patients With Epidermal Growth Factor Receptor (EGFR) Mutation-positive Non-small Cell Lung Cancer(NSCLC)

Carcinoma, Non-Small-Cell Lung

Japan
Bayer

Active, not recruiting

A Study in Which Non-metastatic Castration-resistant Prostate Cancer (nmCRPC) Patients for Whom a Decision to Treat With Darolutamide Has Been Made Before Enrollment Are Observed and Certain Outcomes Are Described (DAROL)

Prostate Cancer

United States, Canada, Japan, Spain, Germany, Belgium, Argentina, Austria, Brazil, Greece, Italy, Russian Federation, Taiwan, China, Denmark, France, Colombia
Haihe Biopharma Co., Ltd.

Recruiting

Assessment of Anti-tumor and Safety in Glumetinib in Patients With c-MET-positive Non-Small Cell Lung Cancer

C-Met Exon 14 Mutation

China, Japan, United States
Dizal Pharmaceuticals

Active, not recruiting

Assessing an Oral EGFR Inhibitor, Sunvozertinib in Patients Who Have Advanced Non-small Cell Lung Cancer With EGFR or HER2 Mutation (WU-KONG1)

Non-Small Cell Lung Cancer

Korea, Republic of, Spain, United States, France, Taiwan, Italy, China, Argentina, Australia, Malaysia, Canada, Japan, Chile
Southern Tohoku BNCT Research Center

Active, not recruiting

Dose Optimized BNCT for Head and Neck Cancer (ST-BNCT2001)

Head and Neck Cancer | Squamous Cell Carcinoma

Japan
AstraZeneca

Active, not recruiting

Durvalumab ± Tremelimumab in Combination With Platinum Based Chemotherapy in Untreated Extensive-Stage Small Cell Lung Cancer (CASPIAN) (CASPIAN)

Small Cell Lung Carcinoma Extensive Disease

Germany, United States, Poland, Taiwan, Turkey, Italy, Korea, Republic of, Brazil, Czechia, Hungary, Japan, Russian Federation, China, Netherlands, Spain, Israel, Ukraine, Austria, France, Bulgaria, Romania, Argentina, Slovakia
Hoffmann-La Roche

Active, not recruiting

A Study of Tiragolumab in Combination With Atezolizumab Compared With Placebo in Combination With Atezolizumab in Patients With Previously Untreated Locally Advanced Unresectable or Metastatic PD-L1-Selected Non-Small Cell Lung Cancer (SKYSCRAPER-01)

Non-Small Cell Lung Cancer

Hungary, Korea, Republic of, Australia, Spain, China, Denmark, Italy, Germany, Mexico, Poland, United States, Brazil, Peru, Thailand, Serbia, Switzerland, Japan, Turkey, Netherlands, Austria, Taiwan, Russian Federation, Ukraine, Greece
Amgen

Recruiting

Study Evaluating Safety, Tolerability and Pharmacokinetics (PK) of Tarlatamab in Adults With Small Cell Lung Cancer (SCLC)

Small Cell Lung Carcinoma

United States, Spain, Austria, Switzerland, United Kingdom, France, Australia, Germany, Japan, Taiwan, Poland, Hong Kong, Netherlands
Pfizer

Active, not recruiting

PF-07104091 as a Single Agent and in Combination Therapy

Breast Cancer | Small Cell Lung Cancer | Ovarian Cancer

United States, China, Japan, Mexico, Bulgaria, Argentina
Bayer

Terminated

RONICICLIB / Placebo in Combination With Chemotherapy in Small Cell Lung Cancer (CONCEPT-SCLC)

Small Cell Lung Carcinoma

Belgium, United States, Korea, Republic of, Hungary, Poland, Japan, Germany, Italy, France
Hoffmann-La Roche

Recruiting

A Study Evaluating the Efficacy and Safety of Multiple Therapies in Cohorts of Participants With Locally Advanced, Unresectable, Stage III Non-Small Cell Lung Cancer (NSCLC)

Non-Small Cell Lung Cancer

United States, Korea, Republic of, Belgium, Canada, Australia, Brazil, China, Japan, Taiwan, Israel, France, Singapore, Germany, Italy, Spain, Thailand, Sweden, Turkey, Colombia, Costa Rica, Hong Kong, Poland, Chile, United Kingdom, New... and more
AstraZeneca

Recruiting

A Global Study to Assess the Effects of Osimertinib in Participants With EGFRm Stage IA2-IA3 NSCLC Following Complete Tumour Resection (ADAURA2)

Non-Small Cell Lung Cancer

United States, Spain, China, Italy, Turkey, Argentina, United Kingdom, Canada, Germany, Brazil, Vietnam, Thailand, Poland, Russian Federation, Japan, Korea, Republic of, Taiwan, Malaysia, Singapore, Romania
Merck Sharp & Dohme LLC

Active, not recruiting

Efficacy and Safety of Pembrolizumab (MK-3475) Plus Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus Enzalutamide Plus ADT in Participants With Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) (MK-3475-991/KEYNOTE-991)

Metastatic Hormone-Sensitive Prostate Cancer

Taiwan, Poland, United States, Australia, Austria, Brazil, Canada, Chile, China, Colombia, Denmark, Finland, France, Germany, Ireland, Israel, Italy, Japan, Korea, Republic of, Mexico, Netherlands, New Zealand, Peru, Russian Federation, Spai... and more
Hoffmann-La Roche

Active, not recruiting

A Study of Atezolizumab Plus Carboplatin and Etoposide With or Without Tiragolumab in Patients With Untreated Extensive-Stage Small Cell Lung Cancer (SKYSCRAPER-02)

Small Cell Lung Cancer

Taiwan, United States, Hungary, Korea, Republic of, Belgium, United Kingdom, Spain, Brazil, Germany, Poland, Australia, Singapore, Italy, Switzerland, Turkey, Japan, Netherlands, Austria, Greece, Czechia, New Zealand, Russian Federation and more
Novartis Pharmaceuticals

Completed

LDK378 in Crizotinib naïve Adult Patients With ALK-activated Non-small Cell Lung Cancer

Non-Small Cell Lung Cancer

United Kingdom, Taiwan, Belgium, Spain, Canada, Italy, Singapore, Japan, Russian Federation, Hong Kong, Thailand, Korea, Republic of, Norway, Australia, France, Sweden, United States, New Zealand
AstraZeneca

Active, not recruiting

A Global Study to Assess the Effects of MEDI4736 (Durvalumab) in Patients With Locally Advanced or Metastatic Non Small Cell Lung Cancer (ATLANTIC)

Non-Small Cell Lung Cancer

United States, Belgium, France, Italy, Spain, United Kingdom, Canada, Hungary, Poland, Thailand, Germany, Korea, Republic of, Czechia, Japan, Philippines, Taiwan, Singapore, Austria
Novartis Pharmaceuticals

Terminated

Phase Ib Study of TNO155 in Combination With Spartalizumab or Ribociclib in Selected Malignancies

Colorectal Cancer | Gastrointestinal Stromal Tumors | Non-small Cell Lung Carcinoma | Head and Neck Squamous Cell Carcinoma | Esophageal SCC

United States, Germany, Spain, Singapore, Australia, Hong Kong, Belgium, Japan, China
Hoffmann-La Roche

Completed

A Study of Atezolizumab in Combination With Carboplatin or Cisplatin + Pemetrexed Compared With Carboplatin or Cisplatin + Pemetrexed in Participants Who Are Chemotherapy-Naive and Have Stage IV Non-Squamous Non-Small Cell Lung Cancer (NSCLC) (IMpower 132)

Non-Small Cell Lung Cancer

United States, Spain, Korea, Republic of, United Kingdom, Australia, Belgium, China, France, Netherlands, Japan, Hungary, Russian Federation, Taiwan, Ireland, Romania, Israel, Latvia, Italy, Portugal, Austria, Bulgaria, Chile, Ukraine, Argenti... and more
Amgen

Recruiting

Study of AMG 509 in Participants With Metastatic Castration-Resistant Prostate Cancer

Prostate Cancer

Japan, United States, Korea, Republic of, Taiwan, Australia, Spain, Germany, Switzerland, China, Portugal
AstraZeneca
Arcus Biosciences, Inc.

Recruiting

A Global Study to Assess the Effects of Durvalumab + Domvanalimab Following Concurrent Chemoradiation in Participants With Stage III Unresectable NSCLC (PACIFIC-8)

Non-Small Cell Lung Cancer

Korea, Republic of, Philippines, United States, Belgium, Hungary, India, Norway, United Kingdom, France, Canada, Germany, Japan, Malaysia, Taiwan, Greece, Italy, Mexico, Turkey, South Africa, Chile, Brazil, Romania, Spain, Switzerland, ... and more
AstraZeneca

Completed

A Global Study to Assess the Effects of MEDI4736 Following Concurrent Chemoradiation in Patients With Stage III Unresectable Non-Small Cell Lung Cancer (PACIFIC)

Non-Small Cell Lung Cancer

United States, Belgium, France, Germany, Italy, Spain, Canada, Poland, Thailand, Vietnam, Korea, Republic of, Hungary, Japan, Mexico, Peru, Turkey, United Kingdom, Taiwan, Chile, Australia, Israel, South Africa, Netherlands, Greece, Sin... and more
AstraZeneca

Active, not recruiting

A Study of Osimertinib With or Without Chemotherapy as 1st Line Treatment in Patients With Mutated Epidermal Growth Factor Receptor Non-Small Cell Lung Cancer (FLAURA2) (FLAURA2)

Non-Small Cell Lung Cancer

United States, Canada, Thailand, Vietnam, France, Korea, Republic of, Brazil, India, Japan, Peru, Philippines, Russian Federation, China, Taiwan, United Kingdom, Czechia, Chile, Australia, Argentina, Slovakia, South Africa

Clinical Trials on Small Cell Prostate Cancer in Japan

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Belarus

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations